Welcome to our dedicated page for Aveanna Healthcare Holdings news (Ticker: AVAH), a resource for investors and traders seeking the latest updates and insights on Aveanna Healthcare Holdings stock.
Aveanna Healthcare Holdings Inc. reports developments for a home-based healthcare platform serving pediatric and adult patient populations across 38 states. Company updates commonly cover nursing, rehabilitation services, school-based occupational nursing, therapy services, day treatment centers, home health and hospice, enteral nutrition products, case management, and respite care for medically fragile and chronically ill patients.
Recurring AVAH news includes earnings releases, financial guidance, investor presentations and conference participation, as well as clinical quality initiatives such as Heartways program certification. Updates also address community-service programs and operating themes tied to care coordination among payers, physicians, hospitals, and other healthcare providers.
Aveanna Healthcare (NASDAQ: AVAH) updated full-year guidance for fiscal 2025 and provided initial fiscal 2026 guidance on April 4, 2026. FY2025 revenue is now expected at $2.425–$2.445 billion with net income of $181–$220 million and Adjusted EBITDA of $318–$322 million. FY2026 revenue guidance is $2.54–$2.56 billion with Adjusted EBITDA of $318–$322 million. Results are preliminary, unaudited, and subject to change upon completion of year-end close and audit.
Aveanna (NASDAQ: AVAH) announced that management will attend the 44th Annual J.P. Morgan Healthcare Conference in San Francisco and will present on January 14, 2026.
The presentation is scheduled for 9:45 a.m. PST on January 14, 2026, followed by one-on-one investor meetings the same day. Interested parties can listen via a simultaneous webcast at https://ir.aveanna.com/. An online replay will be available for a limited time shortly after the call.
Aveanna (NASDAQ: AVAH) announced that management will participate virtually in the BofA Securities Home Care Conference on December 9, 2025.
Management will present at 12:30 PM ET, hold one-on-one investor meetings the same day, and offer a simultaneous webcast available via the company Investor Relations website with an online replay posted for a limited time.
Aveanna Healthcare (NASDAQ: AVAH) reported Q3 2025 revenue $621.9M (+22.2% YoY) and net income $14.1M versus a prior-year net loss. Q3 Adjusted EBITDA $80.1M (12.9% margin, +67.5% YoY). Nine-month revenue was $1.7707B (+17.7%) with Adjusted EBITDA $235.9M (+83.7%).
The company raised full-year 2025 guidance to revenue >$2.375B and Adjusted EBITDA >$300M. Liquidity: cash of $145.9M, securitization capacity $105.8M, undrawn revolver capacity ~$227M (≈$23M letters of credit). Total indebtedness was $1,490.0M; 2025 Term Loans bear interest at Term SOFR +3.75%. Free cash flow for nine months was $86.2M.
Aveanna Healthcare (NASDAQ: AVAH) announced the pricing of a secondary offering by selling stockholders affiliated with J.H. Whitney Equity Partners VII: 10,000,000 shares priced at $9.00 per share, with underwriters granted a 30-day option to buy up to an additional 1,500,000 shares.
The company will not sell shares or receive proceeds from the Offering. The sale is expected to settle on October 23, 2025, subject to customary closing conditions. A Form S-3 shelf registration (declared effective) and prospectus supplement are available through the SEC EDGAR system.
Aveanna Healthcare (NASDAQ: AVAH) announced on October 21, 2025 that certain selling stockholders affiliated with J.H. Whitney Equity Partners VII have commenced a secondary offering of 10,000,000 shares of common stock, with underwriters granted a 30-day option to purchase up to an additional 1,500,000 shares.
The selling stockholders will receive all net proceeds; the company is not offering shares and will not receive any proceeds from the sale. Jefferies and J.P. Morgan are joint lead book-running managers; Barclays and RBC are bookrunners. A Form S-3 shelf registration (including a prospectus) has been filed and declared effective by the SEC.
Aveanna Healthcare (NASDAQ: AVAH) reported preliminary results for the three-month period ended September 27, 2025. Management expects revenue of $616M–$624M, up ~21.0%–22.6% year-over-year; net income of $11M–$15M, up ~125.7%–135.0% year-over-year; and Adjusted EBITDA of $77M–$81M, up ~61.0%–69.3% year-over-year.
Results are preliminary and unaudited, subject to closing procedures and potential material adjustments. The company disclosed significant non-GAAP adjustments, including $15.7M–$16.9M of fees related to debt modifications and various acquisition and integration costs.
Aveanna (NASDAQ: AVAH) will release its third quarter 2025 results before the market open on Thursday, November 6, 2025, followed by a conference call at 10:00 a.m. ET the same day.
Investors can join the live call by dialing 1-877-407-0789 (U.S.) or 1-201-689-8562 (international). A replay will be available three hours after the call by dialing 1-844-512-2921 (U.S.) or 1-412-317-6671 (international) using passcode 13755427. The telephone replay is available until November 13, 2025, and a simultaneous webcast and online replay will be hosted on the company Investor Relations website at https://ir.aveanna.com/.
Aveanna Healthcare Holdings (NASDAQ: AVAH) announced its management team will participate in the Deutsche Bank Annual Leveraged Finance Conference in Austin, TX on October 15, 2025. During the conference, the management will be available for one-on-one meetings with investors.
Aveanna Healthcare (Nasdaq: AVAH) has successfully completed a significant debt refinancing transaction. The company has refinanced its $886.0 million first lien term loans and secured $439.0 million in incremental first lien term loans, bringing the total to $1.325 billion with extended maturity to 2032.
Additionally, AVAH increased its revolving credit facility from $170.3 million to $250.0 million, extending its maturity to 2030. The company used the proceeds to fully repay its $415.0 million second lien term loans. Barclays Bank PLC and Jeffries Finance LLC acted as co-lead arrangers for the transaction.